These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18497243)

  • 1. [Panitumumab].
    Musch A
    Med Monatsschr Pharm; 2008 Apr; 31(4):122-6. PubMed ID: 18497243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panitumumab: a review of its use in metastatic colorectal cancer.
    Keating GM
    Drugs; 2010 May; 70(8):1059-78. PubMed ID: 20481659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on panitumumab in metastatic colorectal cancer.
    Keating GM
    BioDrugs; 2010 Aug; 24(4):275-8. PubMed ID: 20623992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
    Van Cutsem E; Peeters M; Siena S; Humblet Y; Hendlisz A; Neyns B; Canon JL; Van Laethem JL; Maurel J; Richardson G; Wolf M; Amado RG
    J Clin Oncol; 2007 May; 25(13):1658-64. PubMed ID: 17470858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA drug approval summary: panitumumab (Vectibix).
    Giusti RM; Shastri KA; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 May; 12(5):577-83. PubMed ID: 17522246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Panitumumab-treatment of metastatic colorectal cancer].
    Pikó B
    Magy Onkol; 2009 Jun; 53(2):135-42. PubMed ID: 19581179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
    Bouché O; Beretta GD; Alfonso PG; Geissler M
    Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Panitumumab: in the treatment of metastatic colorectal cancer.
    Hoy SM; Wagstaff AJ
    Drugs; 2006; 66(15):2005-14; discussion 2015-6. PubMed ID: 17100412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panitumumab safety for treating colorectal cancer.
    Stremitzer S; Sebio A; Stintzing S; Lenz HJ
    Expert Opin Drug Saf; 2014 Jun; 13(6):843-51. PubMed ID: 24766434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?
    Lien K; Berry S; Ko YJ; Chan KK
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):81-100. PubMed ID: 25400031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer.
    Saadeh CE; Lee HS
    Ann Pharmacother; 2007 Apr; 41(4):606-13. PubMed ID: 17355997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer.
    Addeo R; Caraglia M; Cerbone D; Frega N; Cimmino G; Abbruzzese A; Del Prete S
    Expert Rev Anticancer Ther; 2010 Apr; 10(4):499-505. PubMed ID: 20397915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer.
    Wu M; Rivkin A; Pham T
    Clin Ther; 2008 Jan; 30(1):14-30. PubMed ID: 18343240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
    Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
    N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
    Giusti RM; Shastri K; Pilaro AM; Fuchs C; Cordoba-Rodriguez R; Koti K; Rothmann M; Men AY; Zhao H; Hughes M; Keegan P; Weiss KD; Pazdur R
    Clin Cancer Res; 2008 Mar; 14(5):1296-302. PubMed ID: 18316547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective panitumumab treatment in patients with heavily pre-treated metastatic colorectal cancer: a case series.
    Tzovaras AA; Karagiannis A; Margari C; Barla G; Ardavanis A
    Anticancer Res; 2011 Mar; 31(3):1033-7. PubMed ID: 21498734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
    Hecht JR; Patnaik A; Berlin J; Venook A; Malik I; Tchekmedyian S; Navale L; Amado RG; Meropol NJ
    Cancer; 2007 Sep; 110(5):980-8. PubMed ID: 17671985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.
    Sartore-Bianchi A; Moroni M; Veronese S; Carnaghi C; Bajetta E; Luppi G; Sobrero A; Barone C; Cascinu S; Colucci G; Cortesi E; Nichelatti M; Gambacorta M; Siena S
    J Clin Oncol; 2007 Aug; 25(22):3238-45. PubMed ID: 17664472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panitumumab : leading to better overall survival in metastatic colorectal cancer?
    Sebio A; Stintzing S; Stremitzer S; Zhang W; Lenz HJ
    Expert Opin Biol Ther; 2014 Apr; 14(4):535-48. PubMed ID: 24593265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.